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New drugs must be deemed safe and effective by the
Food and Drug Administration (FDA) before they are
made available to the public. The FDA can also with-
draw drugs from the market if unexpected adverse ef-
fects are detected in postmarketing surveillance after
initial approval. The U.S. General Accounting Office
(GAO) reviewed ten prescription drugs withdrawn from
the market during the period of January 1997 and De-
cember 2000 and found that 8 out of the 10 drugs were
withdrawn due to adverse events occurring predomin-
antly in women. Women were at greater risk for valvular
heart disease for the appetite suppressants fenfluramine
and dexfenfluramine, and Torsades de Pointes for the
antihistamines terfenadine and astemizole [1]. In fact,
the FDA filed a public health advisory in 1997 noting
that valvular heart disease discovered in patients receiv-
ing fenfluramine and phentermine were all women [2]
and women were found to make up 70% of adverse
event reports of Torsades de Pointes that was induced
by drugs that prolong cardiac repolarization [3]. The
FDA also is responsible for determining indications and
dosing for approved drugs. On May 14, 2013, the FDA
issued a safety communication approving label changes
to zolpidem-containing medications for treatment of in-
somnia and recommended significantly lower doses in
women for immediate-release products because women
are more susceptible than men to the risks posed by
“next-day impairment of driving and other activities that
require full alertness” [4]. This was a landmark decision
by the FDA since no prior FDA labels recommended dif-
ferent dosages for men and women if the product was
intended for use by both sexes.
Why were these sex differences discovered only after
the drug was marketed? A 1992 GAO study [5] sug-
gested that a major reason has been the lack of repre-
sentation of women in clinical trials, and most likely, as* Correspondence: sandberg@georgetown.edu
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distribution, and reproduction in any mediuma direct result of the 1977 FDA guidelines [6] that effect-
ively excluded women of childbearing age from participating
in clinical trials. Once President Clinton signed the National
Institutes of Health (NIH) Revitalization Act into law in
1993, which included a mandate that the NIH ensure that
women are included in all research involving human sub-
jects, clinical research was transformed. Since then, not only
government-funded, but also pharmaceutical-funded clinical
trials have routinely included substantial numbers of
women. Yet, even after 1993, there were more reports of un-
expected adverse events in women than men during post-
marketing surveillance [1]. Why?
To address this question, it is necessary to understand
the phases of clinical trials that a candidate drug must
pass before it is considered by the FDA for market ap-
proval. Before large Phase III/IV clinical trials are initi-
ated to confirm the efficacy and safety of a new drug in
clinical populations, potential new therapeutics are
tested for safety in Phase I trials. Once a drug passes ac-
cepted safety standards, efficacy testing using quantita-
tive outcome measures begins in Phase II; however,
these Phase I and II studies are not required to compare
dose and efficacy between the sexes. In fact, out of all
the bioequivalence studies submitted to the Center for
Drug Evaluation and Research between 1977 and 1995,
29 included data addressing sex differences in drug ab-
sorption and of those 29, only 26 met the statistical cri-
terion for sex difference analysis [7]. Thus, the lack of
comparison of dose and efficacy as a function of sex
prior to the design of larger Phase III/IV clinical trials
could be an explanation for why unexpected adverse
events can exhibit a sex bias towards women since
women are underrepresented in early phase clinical tri-
als. For example, Pinnow et al. [8] showed that of the
Phase I trials approved by the FDA between 2006 and
2007, only 32.5% of the participants were women. In an
in-depth analysis of new medical entities approved by
the FDA during 2000–2002, Yang et al. [9] found that al-
though there has been overall progress in the inclusion
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ticipation by class of drug (e.g., women were underrepre-
sented in drugs targeting renal and cardiovascular
disease) and there were no mandatory FDA require-
ments for prospectively designing clinical trials to inves-
tigate the impact of one’s sex or in conducting the
appropriate and complete analyses by sex. All of these
factors could contribute to sex differences in adverse
events.
The study by Kwekel et al. [10] just published in this
journal illustrates why sex bias in basic biomedical re-
search provides an additional explanation for the greater
occurrence of unexpected adverse events in women than
men. Using whole genome microarray gene expression
analysis of kidneys from male and female rats at differ-
ent ages, they identified hundreds of genes (841) that are
differentially expressed in a sex-specific manner at one
or more ages across the life span of rats and 114 sex-
biased genes (69 female-biased and 45 male-biased) that
were common to all three age groups examined. These
findings support previous studies demonstrating sexually
dimorphic gene expression. In 2006, Yang et al. [11]
performed microarrays on multiple somatic tissues of
large numbers of mice derived from an intercross be-
tween inbred mouse strains, and showed that hundreds
of mouse genes were expressed in the brain in a sexually
dimorphic manner while thousands of genes were sexu-
ally dimorphic in liver, adipose tissue, and muscle. Van
Nas et al. [12] then showed in mouse liver that sex dif-
ferences in gene expression are in large part due to
activational effects of gonadal hormones in adulthood,
although gonadal hormone-independent sex chromo-
some effects also contributed to sex-biased gene expres-
sion. By showing how age impacts sex differences in the
organization of renal gene expression networks, Kwekel
et al. support and extend the previous study by Van Nas
et al., which uncovered sex-specific gene expression net-
works related to genetic and metabolic traits (especially
in adipose and liver tissue) as well as gonadal hormone
status.
Early diagnosis of drug-induced kidney injury is a key
factor in pharmaceutical safety and decision making. Of
major concern is the finding by Kwekel et al. [10] that
five out of the six gene products qualified by the FDA
for use in preclinical monitoring of disease and drug-
induced nephrotoxicity [13] exhibit major sex differences
in mRNA expression including kidney injury molecule 1,
clusterin, trefoil factor 3c, osteopontin and lipocalin 2.
For example, kidney injury molecule 1 exhibits a 23-fold
sex difference in mRNA expression at the age (8 weeks)
at which in vivo toxicity evaluations in animals are most
commonly conducted; however, biomarker performance
testing that led to FDA qualification of these biomarkers
were predominantly conducted in male animals [14].Kwekel et al. also found sexual dimorphic mRNA ex-
pression of renal transporters critically involved in drug
uptake and excretion (e.g., Slco1a1, Slc22a7, Slc22a2
and Abcg2) with two transporters that handle a major
portion of prescribed drugs (i.e., Slco1a1 and Slc22a7)
exhibiting directly opposite sex-biased gene expression.
Taken together, these findings strongly indicate signifi-
cant differences in the biology of renal protein expres-
sion and urinary excretion exist between males and
females. Thus, one potential reason adverse events are
more common in women than men is because the
choice of drug targets are male-biased as a result of the
male bias in basic biomedical research (i.e., at the stage
of drug target identification). While there is a growing
awareness of sex differences in the pharmacokinetics
and pharmacodynamics of drug action [15], basic sci-
ence research is still predominantly conducted using
male animals. A survey of animal research published in
major journals in 2009 across ten different disciplines re-
vealed a male bias in eight out of ten fields surveyed includ-
ing neuroscience, physiology, pharmacology, endocrinology,
zoology, and behavior [16]. Studies in cell culture are
also predominantly conducted in XY cells even though
sex-specific pathways in cell fate and mechanisms of
cell death exist and play critical roles in numerous hu-
man pathologies [17].
Discussion
Title IX is a U.S. federal law enacted in 1972 that bans
sex discrimination in any federally-funded education
program. The U.S. Department of Justice reported in
June 2012 that Title IX by providing girls and women
equal access to education, has dramatically expanded
women’s access to athletic programs and increased their
educational attainment [18]. Before Title IX, only one in
27 girls played in varsity high school sports, whereas by
2001 one in every 2.5 girls participated. Since 1972, the
number of female athletes in college has increased by
450%. Not only are there long-lasting health benefits
from engaging girls and women in athletics, women who
are more active in sports have more self-confidence,
team-building and leadership skills. In fact, 80% of fe-
male managers of Fortune 500 companies have a sports
background. As of March 2013, National Collegiate Ath-
letic Association scholarships virtually nonexistent be-
fore Title IX now exceed $960 million for women, which
has contributed to the increase in percentage of women
enrolled in college. Last year, at the 40th anniversary of
Title IX, President Obama commented on many of these
positive aspects including that this law “has helped to
make our society more equal in general”.
President Clinton’s actions in 1993 had a landmark posi-
tive effect on reducing sex discrimination in federally
funded clinical research. Is now the time to eliminate sex
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search? We strongly feel it is for multiple reasons. First, it
is extremely wasteful to develop a drug that ends up being
removed from the market during the late stages of drug
development because of adverse consequences in women.
Second, by not investigating basic biological mechanisms
in the female from the outset, we fail to understand the
full biology and pathophysiology of girls and women.
Third, we need to capitalize on the clues to disease that
are reflected in the sex differences underlying observations
like the onset of hypertension occurs earlier in men than
women [19] and autoimmune diseases such as multiple
sclerosis are more prevalent in women than men [20].
These comparisons will very likely uncover new drug tar-
gets for treating these devastating diseases, which is espe-
cially important given that we are now in an era where the
drug discovery pipeline is shrinking; there were 50% fewer
new drugs approved by the FDA and other major regula-
tory bodies between 2005–2010 than the previous five
years [21].
Some individuals may argue that we are doing suffi-
cient basic research in females when we carefully work
out detailed mechanisms in males and then compare ex-
pression levels of one or two components in the eluci-
dated male pathway to those in the female. But how can
this extrapolation make biological sense when Kwekel
et al. [10] have shown that whole gene networks crucial
to biological pathways such as xenobiotic metabolism
(cytochrome P450 enzymes and drug transporters) show
major sexual dimorphic gene expression as a function of
age across the life span? Sex-biased gene networks in fe-
male kidneys were over-represented in drug metabolism
while male-biased gene networks were over-represented
in renal dysfunction. These findings strongly argue that
males and females exhibit distinct renal biology that is
highly likely to impact the pharmacokinetics and pharma-
codynamics of drug action. Given the inherent complexity
of common chronic medical conditions, and the contribu-
tions of multiple genes to their etiology, it is imperative
that we understand the full spectrum of gene networks
within each sex and not simply extrapolate in a
fragmented manner the function of one or two isolated
genes in the female, as we now commonly do, from what
we know mechanistically in-depth happens in the male
(or vice-versa). Systems biology also cautions against this
type of fragmented extrapolation when the goal is to
understand complex traits. Systems biology research em-
phasizes the value of investigating principal networks of
disease at the whole-body level and to integrate multiple
processes like cell proliferation, metabolism and inflam-
mation into complex disease settings like cardiovascular
disease [22].
A major step to advancing healthcare requires the dis-
covery of new cost-effective medicines; however, theproductivity of the research and development (R&D) in-
dustry has been decreasing in recent years in part due to
the enormous costs associated with drug discovery. Paul
et al. [23] estimated a capitalized cost per launch of $1.8
billion using an R&D model that incorporates the prob-
ability of technical success, cost and cycle time starting
from the point at which drugs are screened for specific
drug targets (preclinical development) through Phase I,
II and III/IV, the FDA approval process and the final
launch of the new medicine. Their model, however, does
not incorporate the cost of the basic biomedical research
that serves as the foundation for identifying potential
drug targets. Drug targets include biochemical com-
pounds in the body such as DNA, RNA, proteins, gly-
cans, lipids and small molecules, whose actions or
absence of actions can result in disease processes. Most
drug targets are discovered through basic biomedical re-
search investigating physiological and pathophysiological
mechanisms in biology, and the vast majority of funding
for basic biomedical research comes from taxpayer dol-
lars that are managed by the NIH.Conclusions
Given the remarkable sex differences that exist in disease
including in the incidence, age of onset, symptoms, re-
sponse to treatment and outcomes, isn’t it time to ex-
tend the basic principles embodied in Title IX that ban
sex discrimination in education to also eliminate sex dis-
crimination in biomedical research? Shouldn’t the move-
ment started in this direction by the NIH revitalization
Act of 1993 now include basic biomedical research? Can
we afford to withdraw potential drugs at the final stages
of drug development due to unforeseen adverse events
in women, or to stop drug development along the way
because a drug is less effective in one sex than the other?
Can we afford to miss out on potential new drug targets
by heavily biasing our drug discovery process towards
male physiology and pathophysiology? Would a Title IX
for basic biomedical research ensure that diminishing re-
sources for research and R&D dollars are spent on dis-
covering and developing drugs that optimally benefit
both men and women, and reduce the investment losses
of drugs that end up shelved, withdrawn or misused by
physicians because of ineffectiveness or frequency of ad-
verse events in one sex but not the other? A thoughtful,
reasoned and evidence-based answer in 2013 can only
be a resounding “Yes”!
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